To assess the effects of intravitreal ranibizumab on diabetic retinopathy ( DR ) severity when administered for up to 3 years , evaluate the effect of delayed initiation of ranibizumab therapy on DR severity , and identify baseline patient characteristics associated with the development of proliferative DR ( PDR ) .